H.R. 1120, the "Abolish the Fogarty International Center Act of 2025," contains two short provisions: a short title and a single substantive clause that states, simply, "The John E. Fogarty International Center for Advanced Study in the Health Sciences is abolished."
Though minimal, the bill would have outsized administrative and programmatic consequences if enacted. By abolishing the Center without any implementing language on transfers, funding, personnel, or existing obligations, the measure creates immediate legal and operational ambiguity for NIH, HHS, Fogarty grantees, and international partners — and would require follow-up action to resolve contracts, grants, property, and statutory authorizations.
At a Glance
What It Does
The bill removes the Fogarty International Center by an express statutory abolition: it declares the center "is abolished." The text contains no clauses about transferring programs, terminating or reauthorizing appropriations, or directing which agency or institute (if any) should take over Fogarty functions.
Who It Affects
Directly affected parties would include the Fogarty Center's staff and leadership, NIH administrative units, current and prospective Fogarty grantees and contractors, and foreign and domestic institutions that host Fogarty-supported research and training. Indirectly, congressional appropriations and HHS program offices would handle the practical consequences.
Why It Matters
Abolishing a federally created research center by blunt statutory language is rare and sets a precedent for eliminating line entities inside larger agencies. Because the bill is silent on implementation details, it shifts the hard work — winding down projects, handling grant obligations, and reallocating assets or personnel — to administrative agencies or to subsequent legislation.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
H.R. 1120's operative text is extremely short: after naming a short title the bill declares that the John E. Fogarty International Center "is abolished." There are no further provisions that define an effective date, direct any transfers of programs or funds, or specify how ongoing contracts, grants, or cooperative agreements are to be handled.
The measure therefore accomplishes a formal statutory abolition but leaves the mechanics of closure undefined.
That silence matters. Federal entities are not self-executing in practice: abolishing a named center does not automatically cancel appropriations, nullify valid contracts, or eliminate civil service positions.
Absent implementing direction, HHS and NIH would confront a menu of administrative tasks — whether to stop new awards, how to treat active grants, whether to reassign staff and projects to other NIH institutes, and how to dispose of property and equipment — all while complying with appropriation law, federal employment rules, and contractual obligations.The bill also raises cross-border and programmatic issues. Many Fogarty activities involve long-term relationships with foreign institutions and multi-year cooperative agreements; ending the center without a transition plan could impair those partnerships and create legal exposure for the United States under existing agreements.
Finally, because the text does not amend the broader statutes that authorize NIH or HHS functions, the practical effect could be a gap between congressional intent (abolition) and operational reality (continuing programmatic needs that require either administrative reallocation or new legislation).
The Five Things You Need to Know
H.R. 1120 contains two sections: a short title and a single substantive clause that declares the John E. Fogarty International Center "is abolished.", The bill does not include any language directing the transfer of Fogarty programs, personnel, grants, contracts, property, or funding to another agency or institute.
There is no effective-date, wind-down procedure, or timetable in the bill; its silence leaves agencies to decide whether and when to pause awards, terminate staff, or otherwise wind down operations.
Because the bill does not amend underlying authorizing statutes for NIH or HHS, abolition of the Center by name may not on its own resolve statutory authorizations, appropriations obligations, or programmatic responsibilities.
Practical consequences for active grants, international cooperative agreements, and federal contracts could require separate administrative actions or follow-on legislation to avoid contractual or legal exposure.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
This section provides a conventional short title: "Abolish the Fogarty International Center Act of 2025." Its only effect is to give the bill a citation; it imposes no substantive legal obligation or timeline. Practically, short titles are for reference only and carry no force on implementation.
Abolition of the Fogarty International Center
This is the bill's single operative sentence: it abolishes the John E. Fogarty International Center for Advanced Study in the Health Sciences. The provision accomplishes a statutory deletion of the center's existence, but it does not specify what happens to ongoing programs, appropriated funds, contracts, cooperative agreements, foreign partnerships, or civil service positions. Those omissions are consequential because statutory abolition does not automatically unwind multi-year legal commitments.
What the bill leaves unresolved
The bill contains no implementing directives — no transfer clauses, no rescission of appropriations, no assignment of functions to other NIH components, and no wind-down procedures. That silence transfers responsibility for practical steps to HHS and NIH administrators, and perhaps to appropriators and authorizing committees. Agencies would likely need to develop a closure plan addressing grant closeouts, staff reassignment or separation, property disposition, and notification to foreign partners; failing to do so cleanly could trigger legal disputes or unplanned costs.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Legislative proponents and constituencies favoring consolidation or reduction of federal research offices — they achieve the symbolic and statutory goal of eliminating a named center without building a new organizational structure.
- Other NIH institutes or centers that could receive transferred programs, staff, or grants by administrative action or subsequent legislation — they may expand their portfolios if Congress or HHS reallocates Fogarty functions.
- Private philanthropic funders of global health research — they may find new opportunities to fill gaps left by a smaller federal footprint and to partner with institutions seeking alternative support.
Who Bears the Cost
- Fogarty staff and leadership — they face job uncertainty, potential reassignment, or separation without a statutory transition plan.
- Current Fogarty grantees and foreign research partners — they risk interruptions, reduced funding continuity, or the administrative burden of shifting awards to other funders or institutes.
- NIH and HHS administrative offices — they inherit winding-down responsibilities (closeouts, property disposition, personnel actions) that require time and resources and may create unbudgeted costs.
- Congressional appropriators and authorizers — they may need to craft follow-on legislation or appropriations language to reassign programs, fund ongoing projects, or absorb liabilities created by the abolition.
Key Issues
The Core Tension
The central dilemma is between achieving an immediate statutory elimination of a named federal research center and the practical obligation to responsibly wind down long-term research, grant, and international commitments: the bill solves the symbolic problem of abolishing an entity but creates operational and legal problems that require further, potentially costly, action to resolve.
The bill's blunt approach — a single sentence abolishing the Center — exposes a set of practical trade-offs. Removing a statutory line item without direction forces administrative and legislative actors to fill in the blanks: when do ongoing grants stop, who pays remaining obligations, and where do programs and staff go?
Those are not merely administrative questions; they affect multi-year, multi-country research collaborations and can trigger contractual remedies if not handled according to federal procurement and grant rules.
Implementation will likely require a mix of administrative steps and additional congressional action. Agencies face competing legal duties: to honor valid obligations funded under prior appropriations, to comply with civil service and collective-bargaining obligations, and to obey property-disposition rules.
At the same time, appropriations law limits what agencies can do without explicit funding directions, so realignment without additional appropriations could be constrained. The bill also creates a governance gap: abolishing the named center does not automatically transfer statutory authorities or expertise that other institutes would need to continue certain global health functions, so Congress or HHS would have to decide whether to rebuild capacity elsewhere or accept program attrition.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.